NCT05819658 - GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

October 11, 2024

Study Completion Date

October 11, 2024

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG

GV1001 Placebo

0.9% normal saline

DRUG

GV1001 0.56mg

Lyophilized peptide from hTERT

DRUG

GV1001 1.12mg

Lyophilized peptide from hTERT

Trial Locations (5)

Seoul National University Bundang Hospital, Seongnam-si

Kyung Hee University Hospital, Seoul

Samsung Medical Center, Seoul

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul

Seoul National University Hospital, Seoul